Pipeline Therapeutics
Jules Lee has worked in the clinical operations and research field since 2001. Jules began their career at Polartechnics Limited as a Clinical Research Associate. In 2003, they moved to Quintiles as a Clinical Team Lead. In 2006, they joined Boehringer Ingelheim as a Senior Clinical Research Associate. In 2008, they became a Clinical Program Manager at FibroGen. In 2013, they were a Clinical Project Manager at Medivation. In 2017, they were a Director of Clinical Operations at Cirius Therapeutics. Currently, they are a Director of Clinical Operations at Pipeline Therapeutics.
Jules Lee attended the University of Sydney from 1996 to 1999, where they earned a Bachelor of Medical Science in Immunology and Biochemistry. Jules then returned to the University of Sydney for a Master of Public Health and Community Medicine, which they completed in 2001.
Pipeline Therapeutics
Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination, and axonal repair.